Flag­ship bankrolls quest to cre­ate gene ther­a­py 2.0, with new vi­ral de­liv­ery tech in hand

Count Flag­ship Pi­o­neer­ing in for the long and con­vo­lut­ed chase of new de­liv­ery ve­hi­cles that promise to ex­pand the boom­ing gene ther­a­py field.

Ring Ther­a­peu­tics, its lat­est biotech cre­ation, has a $50 mil­lion com­mit­ment to ex­plore anellovec­tors — a whole new class of vi­ral shells that it claims of­fers the first “re­al al­ter­na­tive” to ade­n­ovirus-as­so­ci­at­ed virus­es, or AAV, ap­proach­es. If proved vi­able, that could open up a whole new fron­tier in­to dis­eases that are cur­rent­ly off lim­its to gene ther­a­py.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN